HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kitano, H. Articles by Muramatsu, M. Search for Related Content PubMed PubMed Citation Articles by Kitano, H. Articles by Muramatsu, M. Social Bookmarking                What's this?

Metabolic Syndrome and Robustness Tradeoffs

¹ Sony Computer Science Laboratories, Inc., Tokyo, Japan
² Systems Biology Institute, Tokyo, Japan
³ Keio University, Tokyo, Japan
⁴ Medicala Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
⁵ ERATO-SORST Kitano Symbiotic Systems Project, Japan Science and Technology Agency, Tokyo, Japan
⁶ Anesthesiology Department, Emory University, Atlanta, Georgia
⁷ Control and Dynamical Systems, California Institute of Technology, Pasadena, California

The metabolic syndrome is a highly complex breakdown of normal physiology characterized by obesity, insulin resistance, hyperlipidemia, and hypertension. Type 2 diabetes is a major manifestation of this syndrome, although increased risk for cardiovascular disease (CVD) often precedes the onset of frank clinical diabetes. Prevention and cure for this disease constellation is of major importance to world health. Because the metabolic syndrome affects multiple interacting organ systems (i.e., it is a systemic disease), a systems-level analysis of disease evolution is essential for both complete elucidation of its pathophysiology and improved approaches to therapy. The goal of this review is to provide a perspective on systems-level approaches to metabolic syndrome, with particular emphasis on type 2 diabetes. We consider that metabolic syndromes take over inherent dynamics of our body that ensure robustness against unstable food supply and pathogenic infections, and lead to chronic inflammation that ultimately results in CVD. This exemplifies how trade-offs between robustness against common perturbations (unstable food and infections) and fragility against unusual perturbations (high–energy content foods and low–energy utilization lifestyle) is exploited to form chronic diseases. Possible therapeutic approaches that target fragility of emergent robustness of the disease state have been discussed. A detailed molecular interaction map for adipocyte, hepatocyte, skeletal muscle cell, and pancreatic ß-cell cross-talk in the metabolic syndrome can be viewed at http://www.systems-biology.org/001/003.html.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?